Genmab — April 2014
-
-
Importantly, JNJ-61186372 effectively inhibited tumor growth in models with mutant EGFR and cMet activation, whereas single agent EGFR inhibitors were less effective. The preclinical data support the clinical development of JNJ-61186372 in patients with lung cancer and other malignancies associated with aberrant EGFR and cMET signaling.
-
We have designed a bispecific EGFR-cMet antibody (JNJ-61186372) with a unique set of mechanisms of action resulting in anti-tumor activity in the EGFR mutant setting, with or without cMet pathway activation. We have demonstrated three mechanisms of action that contribute to the activity of JNJ-61186372: 1) inhibition of ligand-induced phosphorylation of both EGFR and cMet, 2) receptor degradation in vivo, and 3) enhanced ADCC activity.
-
-
jeg gav godt vide hvor langt JNJ-61186372 er fra at lave en IND
-
Spændende. Det lyder som en kommende IND, så er vi også flyvende indenfor bispecifikke antistoffer
-
En IND der og så en IND på Unibody med Lundbeck indenfor 12 måneder så er jeg en glad mand igen
-
Genmab = fondsbørsens svageste aktie. alle analytikerne siger den skal i 300+ inden af dem er interesseret i at købe i 220 - something is wrong here
-
ja lignede en der lige prøvede på at udløse nogle SL
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind